secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001600620-25-000108
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q3 revenue $73.5M (+8%), net income $31.6M; LUPKYNIS sales up 27% YoY, FY guidance raised
--------------------------------------------------------------------------------

- Q3 2025 net product sales of LUPKYNIS $70.6M, up 27% YoY; 9-month $197.2M, up 24%.
- Diluted EPS $0.23 (Q3), up 130% YoY; net income $31.6M, up 119%.
- FY 2025 net product sales guidance raised to $265-270M from $250-260M; total revenue guidance raised to $275-280M.
- Cash from operating activities $44.5M in Q3, up 162% YoY; cash position $351.8M.
- Positive Phase 1 results for aritinercept (BAFF/APRIL inhibitor); clinical studies in two autoimmune diseases planned by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000108/0001600620-25-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000108/auph-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001600620-25-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer